Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations.

Autor:	Daido, Yusuke, Sugiura, Hiroyuki, Ishikawa, Tatsunori, Kuroi, Taiga, Okamoto, Sachiyo, Nomura, Naho, Masunari, Taro, Sezaki, Nobuo, Nannya, Yasuhito, Ogawa, Seishi, Tanimoto, Mitsune
Předmět:	ACUTE myeloid leukemia STEM cell transplantation ALLOIMMUNITY OLDER patients VENETOCLAX GENETIC mutation PRELEUKEMIA
Zdroj:	Case Reports in Oncology; 2023, Vol. 16 Issue 1, p999-1006, 8p
Abstrakt:	Venetoclax and azacitidine combination therapy (VEN+AZA) is a promising novel therapy for elderly or unfit patients with acute myeloid leukemia (AML). Recently, VEN+AZA with subsequent allo-hematopoietic stem cell transplantation has been reported, and human leukocyte antigen-haploidentical peripheral blood stem cell transplantation using posttransplant cyclophosphamide (PTCy-haplo-PBSCT) from related donors appears to be a suitable option. Here, we report two elderly patients with refractory AML harboring an IDH2 mutation, who were successfully treated with VEN+AZA bridged to PTCy-haplo-PBSCT. This report suggests the efficacy and safety of VEN+AZA as a bridging treatment for PTCy-haplo-PBSCT in refractory AML. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.